Read by QxMD icon Read

Leukemia Research

Christina Halsey
No abstract text is available yet for this article.
September 11, 2018: Leukemia Research
Chetasi Talati, Kendra Sweet
Acute myeloid leukemia (AML) is a heterogeneous disease. Until recently, treatment for patients with AML was limited to induction chemotherapy with cytarabine and anthracycline or hypomethylating agents, and, in some instances, allogeneic hematopoietic stem cell transplant. With the recent approval of new therapies-i.e., CPX-351, enasidenib, ivosidenib, gemtuzumab ozogamicin, and midostaurin-a new era in AML treatment has emerged. Comprehensive diagnostic testing, such as cytogenetic and molecular testing, is necessary for establishing patient eligibility for these new agents and should be performed in a timely manner...
September 8, 2018: Leukemia Research
Yasushi Miyazaki, Heinz Tuechler, Guillermo Sanz, Julie Schanz, Guillermo Garcia-Manero, Francesc Solé, John M Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus, Hagop Kantarjian, Andrea Kuendgen, Luca Malcovati, Mario Cazzola, Jaroslav Cermak, Christa Fonatsch, Michelle M Le Beau, Marilyn L Slovak, Valeria Santini, Michael Lübbert, Jaroslaw Maciejewski, Sigrid Machherndl-Spandl, Silvia M M Magalhaes, Michael Pfeilstöcker, Mikkael A Sekeres, Wolfgang R Sperr, Reinhard Stauder, Sudhir Tauro, Peter Valent, Teresa Vallespi, Arjan A van de Loosdrecht, Ulrich Germing, Detlef Haase, Peter L Greenberg
Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5838 patients, respectively)...
September 6, 2018: Leukemia Research
Mary Lynn Savoie, Isabelle Bence-Bruckler, Lothar B Huebsch, Marc Lalancette, Chris Hillis, Irwin Walker, Jeffrey H Lipton, Donna L Forrest, Dennis Dong Hwan Kim
The majority of patients with TKI failure respond to HCT. However, the relapse risk remains high. This study has evaluated transplant outcomes in 223 CML patients with TKI failure due to resistance (n = 132) or intolerance (n = 29), as well as those that were TKI naïve/responding with advanced disease (n = 35) or with chronic phase (CP, n = 27). We studied outcomes according to post-transplant BCR-ABL transcript level within 3 months. With respect to transplant outcomes according to the post-transplant BCR/ABLtranscript level within 3 months, the group failing to achieve a 1...
September 5, 2018: Leukemia Research
Youssoufa M Ousseine, Phyllis N Butow, Pierre Fenaux, Rebecca Dring, Patrick Festy, Léa Restivo, Norbert Vey, Julien Mancini
MDS is a complex and potentially severe disease which can trigger psychological distress. A lack of information received and understood about MDS may also arouse feelings of distress. Low health literacy (HL) might play a role particularly among older patients. Our aim was to assess MDS-related distress and to study the factors associated with it, including medical and non-medical factors such as HL. A self-administered questionnaire was mailed to all members of French and Australian patients' national MDS associations...
September 5, 2018: Leukemia Research
Bruno L Ferreyro, Laveena Munshi, Michael E Detsky, Mark D Minden, Alexandra Cheung, Lisa Burry, Christie Lee
No abstract text is available yet for this article.
August 31, 2018: Leukemia Research
Bruno C Medeiros
No abstract text is available yet for this article.
August 31, 2018: Leukemia Research
David Belada, Vit Prochazka, Andrea Janikova, Vit Campr, Petra Blahovcova, Robert Pytlik, Alice Sykorova, Pavel Klener, Katerina Benesova, Jan Pirnos, Juraj Duras, Heidi Mocikova, Marek Trneny
The rituximab maintenance (RM) therapy for follicular lymphoma is effective and clinically well tolerated, however there is limited data regarding this from the elderly segment of the population. This analysis was performed to evaluate the efficacy of RM in elderly patients 65 years of age and older and to assess the influence of the induction therapy with immunochemotherapy (R-CHEMO) on the treatment outcome in a real world setting. A total of 232 consecutive patients treated with first-line R-CHEMO and RM (RM1 group; n = 158) or observation (RM0 group; n = 74) were analyzed...
August 31, 2018: Leukemia Research
Marc Sorigue, Javier Nieto, Mireia Santos-Gomez, Edurne Sarrate, Maria-José Jiménez, Cristian Morales-Indiano, Laia Lopez-Viaplana, Elisa Orna, Jose-Tomas Navarro, Josep-Maria Ribera, Blanca Xicoy
Myelodysplastic syndrome (MDS) and antithrombotic medication both increase the risk of bleeding. We set out to analyze the prevalence of use, indications and bleeding risk of antithrombotic therapy in patients with MDS in a retrospective, single-center study including all patients with MDS with >20 × 109 /L platelets. 193 patients (59% male, median age 75 years) were included; 122 did not receive antithrombotic treatment, 51 received antiplatelet agents and 20 received anticoagulants. The cumulative incidence of major bleeding was higher in both the antiplatelet group (11...
August 31, 2018: Leukemia Research
Chad A Hudson, W Richard Burack, John M Bennett
The diagnosis of many hematologic malignancies has shifted from being based almost exclusively on morphology and clinical data to include ancillary studies such as flow cytometry. This trend has yet to affect the diagnosis of chronic myelomonocytic leukemia (CMML) as flow cytometry, while being integral in the diagnosis of many hematologic malignancies, has no explicit role in the current WHO criteria for CMML. The absence of WHO-determined criteria for flow cytometry in the diagnosis of CMML is not due to a lack of research on the subject over the years...
August 28, 2018: Leukemia Research
Guru Subramanian Guru Murthy, Naveen Pemmaraju, Ehab Atallah
No abstract text is available yet for this article.
August 24, 2018: Leukemia Research
Shenmiao Yang, Robert Peter Gale, Hongxia Shi, Yanrong Liu, Yueyun Lai, Jin Lu, Xiaojun Huang
BACKGROUND: Chronic lymphocytic leukaemia (CLL) is 10- to 20-fold less common in Asians (including Han Chinese) compared with persons of predominately European descent. Why is unknown but seems predominately genetic. We observed an increasing frequency of new cases of CLL at our Haematology Centre beginning 2011 and wondered why. OBJECTIVE: Determine the cause(s) for this increased frequency. METHOD: We interrogated the context of CLL diagnosis in 483 consecutive subjects seen at the Institute of Haematology of a large referral hospital in Beijing...
August 22, 2018: Leukemia Research
K Rady, P Blombery, D A Westerman, M Wall, M Curtis, L J Campbell, J F Seymour
Cytotoxic chemotherapy has inherent mutagenic potential and alters the bone marrow microenvironment after therapy. In some cases, this potentiates expansion of an aberrant clone and may lead to a therapy-related myeloid neoplasm if the clone overcomes selective pressure. We present the case of a 43-year-old woman diagnosed with an indolent, therapy-related myeloid neoplasm with an isolated chromosome 6p abnormality following treatment for de novo Acute Myeloid Leukaemia (AML), who manifest a sustained spontaneous cytogenetic remission two years later, possibly due to an ineffectual or non-dominant founding clone...
August 16, 2018: Leukemia Research
Elizabeth Anderson, Priyanka Mehta, Jonathan Heywood, Barbara Rees, Heather Bone, Gareth Robinson, Darren Reynolds, Vyv Salisbury, Lawrence Mayer
CPX-351, a liposomal formulation co-encapsulating cytarabine and daunorubicin (DNR) in a synergistic 5:1 M ratio, has shown favourable response in newly diagnosed elderly high-risk AML. This study assessed intracellular ara-CTP levels following in vitro exposure of human immortalised leukaemic cell lines and primary AML blasts to CPX-351, and investigated fludarabine potentiation of intracellular ara-CTP formation from CPX-351. Comparison of intracellular handling of CPX-351 to cytarabine in HL-60 cells indicated slower conversion to ara-CTP for CPX-351, but equivalent cytotoxicity to cytarabine and combined DNR/cytarabine (DA) at 48 h, mostly likely reflecting the need for intracellular liposome processing to release encapsulated drugs...
August 11, 2018: Leukemia Research
Qian Li, Shuang Gao, Jing Ma, Su Liu, Yuanfang Yue, Lin Chen, Han Li, Xue Wang, Dongying Li, Zeng Cao, Zhigang Zhao, Xiaofang Wang, Yong Yu, Yizhuo Zhang, Yafei Wang
Peripheral T-cell lymphomas-not otherwise specified (PTCL-NOS) generally have poor patient outcomes, with a 5-year survival rate of ∼32%. The most common prognostic system for patients with PTCL-NOS, the PTCL-U score, is often inadequate because it does not take into consideration the role of host immunity or the microenvironment induced by the tumor. In this paper we aimed to determine the correlation between the Absolute Lymphocyte Count/Absolute Monocyte Count (ALC/AMC) ratio and the prognosis of PTCL-NOS...
July 26, 2018: Leukemia Research
Tomas Radivoyevitch, Robert M Dean, Bronwen E Shaw, Ruta Brazauskas, Heather R Tecca, Remco J Molenaar, Minoo Battiwalla, Bipin N Savani, Mary E D Flowers, Kenneth R Cooke, Betty K Hamilton, Matt Kalaycio, Jaroslaw P Maciejewski, Ibrahim Ahmed, Görgün Akpek, Ashish Bajel, David Buchbinder, Jean-Yves Cahn, Anita D'Souza, Andrew Daly, Zachariah DeFilipp, Siddhartha Ganguly, Mehdi Hamadani, Robert J Hayashi, Peiman Hematti, Yoshihiro Inamoto, Nandita Khera, Tamila Kindwall-Keller, Heather Landau, Hillard Lazarus, Navneet S Majhail, David I Marks, Richard F Olsson, Sachiko Seo, Amir Steinberg, Basem M William, Baldeep Wirk, Jean A Yared, Mahmoud Aljurf, Muneer H Abidi, Heather Allewelt, Amer Beitinjaneh, Rachel Cook, Robert F Cornell, Joseph W Fay, Gregory Hale, Jennifer Holter Chakrabarty, Sonata Jodele, Kimberly A Kasow, Anuj Mahindra, Adriana K Malone, Uday Popat, J Douglas Rizzo, Harry C Schouten, Anne B Warwick, William A Wood, Mikkael A Sekeres, Mark R Litzow, Robert P Gale, Shahrukh K Hashmi
BACKGROUND: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). METHODS: 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. RESULTS: 335 MDS/AML cases were diagnosed posttransplant (3...
July 19, 2018: Leukemia Research
Gayane Manukyan, Peter Turcsanyi, Zuzana Mikulkova, Gabriela Gabcova, Renata Urbanova, Petr Gajdos, Veronika Smotkova Kraiczova, Sarka Zehnalova, Tomas Papajik, Eva Kriegova
There is the first evidence of changes in the kinetics of B cell antigen receptor (BCR) internalisation of neoplastic cells in chronic lymphocytic leukemia (CLL) after the short-term and long-term administration of ibrutinib. We aimed to assess the influence of short-term and long-term ibrutinib treatment on the HLA-DR expression on CLL cells, T cells and monocytes. The immunophenotyping of CLL and immune cells in peripheral blood was performed on 16 high-risk CLL patients treated with ibrutinib. After early ibrutinib administration, the HLA-DR expression on CLL cells reduced (P = 0...
September 2018: Leukemia Research
Dandan Li, Tara L Lin, Brea Lipe, Richard A Hopkins, Heather Shinogle, Omar S Aljitawi
Acute myeloid leukemia (AML) relapse results from the survival of chemotherapy-resistant and quiescent leukemia stem cells (LSC). These LSCs reside in the bone marrow microenvironment, comprised of other cells and extracellular matrix (ECM), which facilitates LSC quiescence through expression of cell adhesion molecules. We used decellularized Wharton's jelly matrix (DWJM), the gelatinous material in the umbilical cord, as a scaffolding material to culture leukemia cells, because it contains many components of the bone marrow extracellular matrix, including collagen, fibronectin, lumican, and hyaluronic acid (HA)...
September 2018: Leukemia Research
Xue Chen, Fang Wang, Yang Zhang, Mangju Wang, Wenjun Tian, Wen Teng, Xiaoli Ma, Lei Guo, Jiancheng Fang, Ying Zhang, Ping Zhu, Hongxing Liu
Fusion genes are major molecular biological abnormalities in hematological malignancies. To depict the common recurrent gene-fusion landscape in acute lymphoblastic leukemia (ALL), 36 recurrent fusion genes in hematologic malignancies were assessed using multiplex-nested RT-PCR in 2479 patients with de novo ALL. 17 kinds of distinct fusion genes were detected in 712 (28.72%) cases. Co-occurrence of different fusion genes was observed in 6 (0.24%) patients. Incidence of fusion genes in B-ALL was significantly higher than in T-ALL (31...
September 2018: Leukemia Research
Somprakash Dhangar, Selvaa Kumar C, Chandrakala S, Babu Rao Vundinti
No abstract text is available yet for this article.
September 2018: Leukemia Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"